title: Targeting the complement system in systemic lupus erythematosus and other diseases.
abstract: The importance of the complement system in the pathogenesis of systemic lupus erythematosus (SLE) has long been recognized. However, despite an unprecedented amount of SLE clinical trial activities ongoing at this time, complement inhibitors have been omitted from the therapeutic assault on this disease. We review data generated from murine lupus that provide scientific support for the study of human SLE. Also reviewed is the sole study of a complement inhibitor, eculizumab, performed in patients with SLE. We conclude with a review of other inflammatory diseases where ongoing programs might provide the groundwork for the development of complement inhibitors in SLE.
authors.affiliation: Division of Rheumatology and Allergy-Immunology, North Shore-Long Island Jewish Health System, Hofstra North Shore-LIJ School of Medicine, 865 Northern Boulevard Suite 302, Great Neck, NY 11021, USA.
authors.forename: Maria-Louise
authors.initials: ML
authors.lastname: Barilla-Labarca
authors.forename: Kiley
authors.initials: K
authors.lastname: Toder
authors.forename: Richard
authors.initials: R
authors.lastname: Furie
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D051056:Complement Inactivating Agents / Q000627:therapeutic use*; D003165:Complement System Proteins / Q000502:physiology; D001026:Coronary Artery Bypass; D003882:Dermatomyositis / Q000188:drug therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000209:etiology; D009393:Nephritis / Q000188:drug therapy; D014657:Vasculitis / Q000188:drug therapy
chemical_list: D051056:Complement Inactivating Agents; D003165:Complement System Proteins
keywords: Complement; Complement inhibitors; Eculizumab; Lupus nephritis; Systemic lupus erythematosus; Treatment